Drug Trial Radar · NCT04908189
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
729
Actual
Start
Jul 15, 2021
Primary completion
Nov 7, 2024
Study completion Nov 12, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
Conditions
- Psoriatic Arthritis
Interventions
DeucravacitinibDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
ApremilastDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16Time frame: Week 16
Locations
138 sites in 18 countries. Site status is shown where the registry gives one.
Local Institution - 0149
Mountain Brook, Alabama
Local Institution - 0212
Sacramento, California
Local Institution - 0188
Whittier, California
Local Institution - 0192
Skokie, Illinois
Local Institution - 0203
Hopkinsville, Kentucky
Local Institution - 0195
Baton Rouge, Louisiana
Local Institution - 0169
Cumberland, Maryland
Local Institution - 0034
Okemos, Michigan
Local Institution - 0133
Eagan, Minnesota
Local Institution - 0109
Hattiesburg, Mississippi
Local Institution - 0108
New York, New York
Local Institution - 0186
Rochester, New York
Local Institution - 0196
Charlotte, North Carolina
Local Institution - 0180
Cleveland, Ohio
Local Institution - 0189
Oklahoma City, Oklahoma
Local Institution - 0147
Portland, Oregon
Local Institution - 0016
Duncansville, Pennsylvania
Local Institution - 0182
Summerville, South Carolina
Local Institution - 0167
Lubbock, Texas
Local Institution - 0070
Mesquite, Texas
Local Institution - 0184
Plano, Texas
Local Institution - 0187
Seattle, Washington
Local Institution - 0190
Franklin, Wisconsin
Local Institution - 0175
Milwaukee, Wisconsin
Local Institution - 0200
Buenos Aires, Argentina
Local Institution - 0048
La Plata, Buenos Aires, Argentina
Local Institution - 0038
San Isidro, Buenos Aires, Argentina
Local Institution - 0039
CABA, Distrito Federal, Argentina
Local Institution - 0171
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0003
Botany, New South Wales, Australia
Local Institution - 0018
Parramatta, New South Wales, Australia
Local Institution - 0004
Maroochydore, Queensland, Australia
Local Institution - 0099
Woodville, South Australia, Australia
Local Institution - 0002
Camberwell, Victoria, Australia
Local Institution - 0017
Geelong, Victoria, Australia
Local Institution - 0078
Brussels, Belgium
Local Institution - 0058
Ghent, Belgium
Local Institution - 0061
Liège, Belgium
Local Institution - 0001
Québec, Canada
Local Institution - 0111
Vancouver, British Columbia, Canada
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.